Patient Support

What is myleukaemia?

Myleukaemia offers precision oncology for hematological conditions using advanced organ-on-chip technology.

How does the process work?

We analyze patient cells in our lab, testing therapies and providing a detailed report within 72 hours.

What are organ-on-chip avatars?

Organ-on-chip avatars simulate bone marrow environments, allowing us to evaluate treatment responses accurately and efficiently.

This technology enhances personalized treatment decisions for patients.

Who can access the reports?

How to get started?

Patients can initiate the process through their healthcare provider.

Delfim Duarte, MD, PhD

Clinical Haematologist at IPO-Porto, KOL in Leukaemia, Group Leader at i3S and invited Professor at FMUP, UP +40 papers in top peer-reviewed journals with +1500 citations and H-index of 19.

Cristina Barrias, PhD

KOL Bioengineering, Group Leader at i3S/INEB and invited Professor at ICBAS, UP +97 papers in top peer-reviewed journals with +6400 citations and H-index of 41.

Maria José Oliveira, PhD

KOL Tumor Immunology, Group Leader at i3S/INEB and invited Professor at ICBAS, UP +120 papers in top peer-reviewed journals with +5000 citations and H-index of 42.

Advisory board & Mentors

Cristina Spinola, MSc

Patient representative with first-hand experience in Multiple Myeloma cancer patient caretaker. Experience in pharmaceutical industry sales.

Tomás Lamas, MD

MD at ICU Department, Hospital Egas Moniz & patient representative with first-hand experience in AML cancer patient caretaker. Founder of Batazu Family initiative (https://batazu.com/)